Drugs / Obinutuzumab β
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07696377 | Jul 2026 → Jan 2030 expected | chronic inflammatory demyelinating polyradiculoneuropathy | Zhongming Qiu | Not yet recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05314010 | Aug 2022 → Feb 2025 overdue | neuromyelitis optica | Beijing Mabworks Biotech Co., Ltd. | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | obinutuzumab β | “Safety and Efficacy of Obinutuzumab β (MIL62), a Novel Glycoengineered Type II Anti-CD20 Monoclonal Antibody, in Patients with Neuromyelitis Optica Spectrum Disorder: A...” PMID 42177718 ↗ May 2026 |
| Known as | MIL62 | “Safety and Efficacy of Obinutuzumab β (MIL62), a Novel Glycoengineered Type II Anti-CD20 Monoclonal Antibody, in Patients with Neuromyelitis Optica Spectrum Disorder: A...” PMID 42177718 ↗ May 2026 |
| Modality | Monoclonal antibody | “a novel glycoengineered type II anti-CD20 monoclonal antibody” PMID 42177718 ↗ May 2026 |
| Route | Intravenous | “Administer Obinutuzumab β Injection 600mg intravenously” NCT07696377 ↗ |